Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

THVD-201 is a novel combination of a muscarinic antagonist (tolterodine) and a muscarinic agonist (pilocarpine).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: TheraVida, Inc.
• Treatments: Pilocarpine; Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Healthy males, 18 - 45 years of age.

• BMI 20-30 m2.

Exclusion Criteria:

• Subjects who have a history of sensitivity to antimuscarinic or muscarinic agents or related derivatives.

• Clinically significant ECG, vital signs and clinical laboratory indices.